Starling Oncology, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M | $187.5M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | — | — | — | — | — |
| SG&A Expense | $105.6M | $107.8M | $113.9M | $119.7M | $83.4M | $41.9M |
| Operating Income | $-36.1M | $-60.1M | $-77.0M | $-82.0M | $-45.9M | $-8.2M |
| Operating Margin | -7.2% | -15.3% | -23.8% | -32.5% | -22.6% | -4.4% |
| Interest Expense | — | — | — | — | $320.0K | $347.0K |
| Pretax Income | $-60.7M | $-64.7M | $-83.1M | $-91.0K | $-11.6M | $-14.8M |
| Income Tax Expense | $-131.0K | $0 | $-36.0K | $-243.0K | $-671.0K | $-493.0K |
| Net Income | $-60.6M | $-64.7M | $-83.1M | $152.0K | $-10.9M | $-14.3M |
| Net Margin | -12.1% | -16.4% | -25.6% | 0.1% | -5.4% | -7.6% |
| EPS (Basic) | $-0.54 | $-0.71 | $-0.92 | $0.00 | $-0.16 | $-0.24 |
| EPS (Diluted) | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 | $-0.24 |
| Shares Outstanding (Basic) | 92.4M | 75.0M | 73.7M | 72.8M | 66.2M | 59.1M |
| Shares Outstanding (Diluted) | 92.4M | 75.0M | 73.7M | 80.6M | 66.2M | 59.1M |
| Dividends Per Share | — | — | — | — | — | — |